Get the Stockscreener App
1.19
0.83%
-0.01
After Hours:
1.18
-0.01
-0.84%
iBio Inc stock is traded at $1.19, with a volume of 616.65K.
It is down -0.83% in the last 24 hours and down -19.05% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$1.20
Open:
$1.23
24h Volume:
616.65K
Relative Volume:
0.80
Market Cap:
$76.53M
Revenue:
$300.00K
Net Income/Loss:
$-27.61M
P/E Ratio:
-2.0599
EPS:
-0.5777
Net Cash Flow:
$-22.17M
1W Performance:
-7.03%
1M Performance:
-19.05%
6M Performance:
-45.41%
1Y Performance:
+49.37%
1-Day Range:
$1.15
$1.24
1-Week Range:
$1.15
$1.3697
52-Week Range:
$0.78
$3.82
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.19 | 76.53M | 300.00K | -27.61M | -22.17M | -0.5777 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-26 | Initiated | Raymond James | Outperform |
| Jun-05-26 | Initiated | B. Riley Securities | Buy |
| Oct-21-25 | Initiated | Oppenheimer | Outperform |
| Oct-17-25 | Initiated | Leerink Partners | Outperform |
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
View All
iBio Inc Stock (IBIO) Latest News
IBIO INC (IBIO) Stock Chart - ChartMill
iBio Inc. Share PriceIBIO, RNS News, Articles, Quotes, & Charts (NASDAQ:IBIO) - proactiveinvestors.com
HC Wainwright Comments on iBio's Q1 Earnings (NASDAQ:IBIO) - MarketBeat
IBIO Q2 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Edge HigherFinancial Data - dars.gov.et
Ibio Stock Price Forecast. Should You Buy IBIO? - StockInvest.us
iBio, Inc. Common Stock (NASDAQ: IBIO) Share Price, IBIO Stock News, IBIO Share Price & Updates - kalkine.com.au
HC Wainwright Upgrades iBio (NASDAQ:IBIO) to Strong-Buy - MarketBeat
H.C. Wainwright Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $7 - Moomoo
iBio stock initiated at buy by H.C. Wainwright with $7 target - Investing.com South Africa
HC Wainwright Initiates iBio With Buy Rating, $7 Price Target - Yahoo Finance
This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
IBIO Initiates Coverage On by HC Wainwright & Co. -- Price Targe - GuruFocus
IBio Price Target Announced at $7.00/Share by HC Wainwright & Co. - Moomoo
HC Wainwright & Co. initiates coverage of iBio with Buy rating, $7 price target - tradingview.com
Ibio, Inc. : H.c. Wainwright Initiates Covera - Moomoo
iBio Inc (0JV0.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 8K Ibio Inc For: 14 September By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
iBio updates corporate presentation, details pipeline milestones and $88M cash runway - TradingView
New iBio (NASDAQ: IBIO) investor presentation goes public - Stock Titan
iBio (NASDAQ:IBIO) Stock Rating Lowered by Wall Street Zen - MarketBeat
iBio, Inc. (IBIO) Stock Price & News - Syfe
IBIO Q2 2026 Earnings: EPS Beat Provides Minor Lift as Revenue Remains AbsentOperating Income Trends - dars.gov.et
iBio at Wells Fargo healthcare conference: obesity pipeline takes shape By Investing.com - Investing.com South Africa
iBio at Wells Fargo healthcare conference: obesity pipeline takes shape - Investing.com
iBio (NASDAQ: IBIO) Shareholders Set to Vote on 500 Million Share Increase on October 14, 2026 - Kalkine Media
iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
iBio, Inc. SEC Filing (Sep 4, 2026) - stocktitan.net
Hundreds of millions of new shares on ballot at iBio (IBIO) - Stock Titan
PharmaCyte Biotech Inc (PMCB) Peer Comparison – Compare with Others - Value Research
iBio, Inc. (NASDAQ:IBIO) Receives Average Rating of "Buy" from Brokerages - marketbeat.com
iBio Q2 EPS Forecast Decreased by Brookline Capital Markets - MarketBeat
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference - manilatimes.net
Insiders Give Up US$33k As iBio Stock Drops To US$1.27 - simplywall.st
iBio Inc. (IBIO) Slides 6.6% to $1.27 as Biotech Stock Approaches Key SupportWyckoff Distribution - dars.gov.et
B. Riley Securities Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $6 - moomoo.com
iBio Advances IBIO-600 Through First Phase 1 Dose Escalation As Cash And Investments Reach $88 Million - Pulse 2.0
iBio Inc. Q2 2026 Earnings: Narrower Loss Per Share Slightly Beats Estimates, Stock Slips 2.86%ROIC Trend Report - dars.gov.et
iBio, Inc. Revenue Breakdown – NASDAQ:IBIO - TradingView
iBio FY2026 Net Loss Widens to $33M on Higher R&D Spending - Minichart
iBio FY 2026: Revenue $100K, Net income ($33.04M), EPS ($0.32) — 10-K Summary - TradingView
iBio reports $33 million loss for fiscal 2026, advances pipeline By Investing.com - Investing.com Canada
IBio Reports $33.0 Million Fiscal 2026 Net Loss as Phase 1 Advances - Moomoo
iBio Reports $33.0 Million Fiscal 2026 Net Loss as Phase 1 Advances - Quiver Quantitative
IBIO: Advanced clinical pipeline and secured funding, extending cash runway into fiscal 2028 - TradingView
iBio (NASDAQ:IBIO) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
iBio reports FY2026 net loss of $33.0M, revenue $0.1M and $88.0M cash and investments - TradingView
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - The Manila Times
iBio Reports Fiscal 2026 Financial Results and Corporate Update Highlighting Clinical and Pipeline Progress - Quiver Quantitative
IBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - marketscreener.com
iBio FY26 Results: Net loss widens 80% to $33.0M, R&D up 136% - scanx.trade
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):